Stock listing

Frankfurt:6C1 CytomX Therapeutics, Inc. Aktie

German listing (Frankfurt) of CytomX Therapeutics, Inc. · home listing NASDAQ:CTMX

Follow CytomX Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · FWB:6C1

€1.96 EUR -0.06 (-3.0%)

Close on Oct 27, 2026

Day range
€1.96 – €1.96 EUROct 27, 2026
Market cap
€426.8M EURAt the close on Oct 27, 2026 · price × 217.9M shares outstanding
CytomX Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CTMX · Home$2.23 USD-0.11 (-4.7%)9,469,880$2.36$2.39$2.14$2.34Close on Nov 2, 2026
Frankfurt:6C1€1.959 EUR-0.062 (-3.0%)—€1.959€1.959€1.959€2.02Close on Oct 27, 2026
Ticker
Frankfurt:6C1
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Cytomx Therapeutics (NASDAQ:CTMX) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 5:00 PM ET

    Register

Replays

  • Cytomx Therapeutics (NASDAQ:CTMX) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 5:00 PM ET

    Watch Transcript

  • Cytomx Therapeutics (NASDAQ:CTMX) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 5:00 PM ET

    Watch Transcript

  • Cytomx Therapeutics (NASDAQ:CTMX) Q4 2025 Earnings Call

    Mon, Mar 16, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Nov 2, 2026

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

Oct 29, 2026

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

Aug 27, 2026

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Aug 6, 2026

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

Aug 3, 2026

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 30, 2026

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

Jul 27, 2026

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Jun 3, 2026

CytomX Therapeutics to Present at Upcoming June Investor Conferences

May 21, 2026

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

May 18, 2026

All CytomX Therapeutics, Inc. news

Decks

CytomX Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 174 in all · newest Nov 2, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Aug 6, 2026
Decks
11 decks · latest Sep 8, 2026

Where CytomX Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CTMX · Home listingNASDAQUnited StatesUSD
gettex:6C1gettexGermanyEUR
LS Exchange:A14158LS ExchangeGermanyEUR
Lang & Schwarz:A14158Lang & SchwarzGermanyEUR
Tradegate:6C1TradegateGermanyEUR
Frankfurt:6C1 · This pageFrankfurtGermanyEUR
BOATS:CTMXBOATSUnited StatesUSD
BX Swiss:6C1BX SwissSwitzerlandCHF
Dusseldorf:6C1DusseldorfGermanyEUR
Stuttgart:6C1StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about CytomX Therapeutics, Inc.